IMMUNIB trial (AIO-HEP-0218/ass): A single-arm, phase II study evaluating safety and efficacy of immunotherapy nivolumab in combination with lenvatinib in advanced-stage hepatocellular carcinoma (HCC).

被引：0
|
作者：
Vogel, Arndt
Siegler, Gabriele Margareta
Siebler, Jurgen
Lindig, Udo
Schultheiss, Michael
Mueller, Tobias
Simon, Henry
Joeckel, Christiane
Mueller, Daniel Wilhelm
Al-Batran, Salah-Eddin
Saborowski, Anna
De Toni, Enrico N.
机构：
[1] Hannover Med Sch, Klin Gastroenterol Hepatol & Endokrinol, Hannover, Germany
[2] Paracelsus Med Univ, Klinikum Nurnberg, Med Klin 5, Hamatol Onkol, Nurnberg, Germany
[3] Univ Klinikum Erlangen, Med Klin 1, Erlangen, Germany
[4] Univ Klinikum Jena, Klin Innere Med Hamtol Onckol 2, Jena, Germany
[5] Univ Klinikum Freiburg, Klin Innere Med 2, Freiburg, Germany
[6] Charite Univ Med Berlin CVK, Med Klin Gastroenterol Infektiol & Rheumatol, Berlin, Germany
[7] Rems Murr Klinikum Winnenden, Hamatol Onkol & Palliat Med, Winnenden, Germany
[8] Inst Klin Krebsforsch IKF Krankenhaus Nordwest, Frankfurt, Germany
[9] 2Krankenhaus Nordwest, Univ Canc Ctr Frankfurt, Frankfurt, Germany
[10] Hannover Med Sch, Klin Gastroenterol Hepatol & Endokrinol, Hannover, Germany
[11] LMU Munchen, Med Klin & Poliklin 2, Munich, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4107
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Venous infusion chemotherapy (VIC) combined with apatinib and camrelizumab for hepatocellular carcinoma (HCC) in CNLC stage III: A prospective, single-arm, phase II trial.
    Peng, Linhui
    Chen, Tao
    Chen, Yajin
    Xu Yunxiuxiu
    Wang, Jie
    Zhong, Guoping
    Xiao, Zhiyu
    Zhou, Zhenyu
    Ye, Congting
    Li, Yong
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [32] Hepatic artery infusion chemotherapy (HAIC) combined with apatinib and camrelizumab for hepatocellular carcinoma (HCC) in BCLC stage C: A prospective, single-arm, phase II trial (TRIPLET study)
    Zhang, T-Q.
    Zuo, M-X.
    Geng, Z-J.
    Huang, Z-L.
    Li, J-B.
    Wu, P-H.
    Gu, Y-K.
    ANNALS OF ONCOLOGY, 2021, 32 : S825 - S825
  • [33] Hepatic artery infusion chemotherapy (HAIC) combined with apatinib and camrelizumab for hepatocellular carcinoma (HCC) in BCLC stage c: A prospective, single-arm, phase II trial (TRIPLET study).
    Gu, Yang-Kui
    Zhang, Tian-Qi
    Zuo, Meng-Xuan
    Geng, Zhi-Jun
    Li, Ji-Bin
    Huang, Zi-Lin
    Wu, Pei-Hong
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [34] A prospective, single-arm, phase II clinical study of tislelizumab in combination with lenvatinib for perioperative treatment of resectable primary hepatocellular carcinoma with high risk of recurrence.
    Song, Tianqiang
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [35] Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial
    Zhang, Wenwen
    Tong, Shuang
    Hu, Bingyang
    Wan, Tao
    Tang, Haowen
    Zhao, Feilong
    Jiao, Tianyu
    Li, Junfeng
    Zhang, Ze
    Cai, Jinping
    Ye, Huiyi
    Wang, Zhanbo
    Chen, Shiqing
    Wang, Yafei
    Li, Xuerui
    Wang, Fangzhou
    Cao, Junning
    Tian, Lantian
    Zhao, Xiaochen
    Chen, Mingyi
    Wang, Hongguang
    Cai, Shouwang
    Hu, Minggen
    Bai, Yuezong
    Lu, Shichun
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (09)
  • [36] Hepatic artery infusion chemotherapy (HAIC) combined with tislelizumab and lenvatinib for initial unresectable hepatocellular carcinoma (HCC) with portal vein tumor thrombus: A prospective, single-arm phase II trial
    Pan, Long
    Sun, Ruirui
    He, Qiang
    Zhou, Yin
    Li, Jiachu
    Gou, Yang
    Wu, Chenrui
    Fu, Zixuan
    Zhao, Yaowu
    He, Qin
    Huang, Ping
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [37] A single arm phase II trial of capecitabine and erlotinib in patients with advanced hepatocellular carcinoma after firstline failure (CAPER- HCC study)
    Srinivas, S.
    Bhargava, P.
    Ramaswamy, A.
    Mandavkar, S.
    Nashikkar, C.
    Naughane, D.
    Ostwal, V.
    ANNALS OF ONCOLOGY, 2023, 34 : S138 - S139
  • [38] A Phase 2, Prospective, Multicenter, Single-arm Trial of Transarterial Chemoembolization Therapy in Combination Strategy with Lenvatinib in Patients with Unresectable Intermediate-stage Hepatocellular Carcinoma: TACTICS-L Trial
    Kudo, Masatoshi
    Ueshima, Kazuomi
    Saeki, Issei
    Ishikawa, Toru
    Inaba, Yoshitaka
    Morimoto, Naoki
    Aikata, Hiroshi
    Tanabe, Nobukazu
    Wada, Yoshiyuki
    Kondo, Yasuteru
    Tsuda, Masahiro
    Nakao, Kazuhiko
    Ito, Takanori
    Hosaka, Tetsuya
    Kawamura, Yusuke
    Kuzuya, Teiji
    Nojiri, Shunsuke
    Ogawa, Chikara
    Koga, Hironori
    Hino, Keisuke
    Ikeda, Masafumi
    Moriguchi, Michihisa
    Hisai, Takashi
    Yoshimura, Kenichi
    Furuse, Junji
    Arai, Yasuaki
    LIVER CANCER, 2024, 13 (01) : 99 - 112
  • [39] Hepatic arterial infusion of oxaliplatin plus raltitrexed in patients with intermediate and advanced stage hepatocellular carcinoma: A phase II, single-arm, prospective study
    Chen, Shiguang
    Zhang, Kongzhi
    Liu, Weifu
    Yu, Wenchang
    EUROPEAN JOURNAL OF CANCER, 2020, 134 : 90 - 98
  • [40] Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial
    Xia, Yongxiang
    Tang, Weiwei
    Qian, Xiaofeng
    Li, Xiangcheng
    Cheng, Feng
    Wang, Ke
    Zhang, Feng
    Zhang, Chuanyong
    Li, Donghua
    Song, Jinhua
    Zhang, Hui
    Zhao, Jie
    Yao, Aihua
    Wu, Xiaofeng
    Wu, Chen
    Ji, Guwei
    Liu, Xisheng
    Zhu, Feipeng
    Qin, Lang
    Xiao, Xuan
    Deng, Zhenhua
    Kong, Xiangyi
    Li, Si
    Yu, Yangyang
    Xi, Wenjing
    Deng, Wanglong
    Qi, Chuang
    Liu, Hanyuan
    Pu, Liyong
    Wang, Ping
    Wang, Xuehao
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (04)
12345